These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 22710467)

  • 1. Zonisamide for the treatment of self-inflicted dermatoses related to impulse control disorders.
    Tribó MJ; Rozas-Muñoz EA; Gallardo F; Casanova N; Ros-Montalban S; Bulbena A; Pujol R
    Arch Dermatol; 2012 Jun; 148(6):762-4. PubMed ID: 22710467
    [No Abstract]   [Full Text] [Related]  

  • 2. Our clinical experience with zonisamide in resistant generalized epilepsy syndromes.
    Kelemen A; Rásonyl G; Neuwirth M; Barcs G; Szucs A; Jakus R; Fabó D; Juhos V; Pálfy B; Halász P
    Ideggyogy Sz; 2011 Mar; 64(5-6):187-92. PubMed ID: 21688720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emotional regulation, dissociation, and the self-induced dermatoses: clinical features and implications for treatment with mood stabilizers.
    Gupta MA
    Clin Dermatol; 2013; 31(1):110-7. PubMed ID: 23245982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of escitalopram in psychogenic excoriation.
    Pukadan D; Antony J; Mohandas E; Cyriac M; Smith G; Elias A
    Aust N Z J Psychiatry; 2008 May; 42(5):435-6. PubMed ID: 18499934
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term efficacy and safety of monotherapy and adjunctive therapy with zonisamide.
    Tosches WA; Tisdell J
    Epilepsy Behav; 2006 May; 8(3):522-6. PubMed ID: 16542880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is adjunctive open-label zonisamide effective for bipolar disorder?
    Ghaemi SN; Shirzadi AA; Klugman J; Berv DA; Pardo TB; Filkowski MM
    J Affect Disord; 2008 Jan; 105(1-3):311-4. PubMed ID: 17586053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zonisamide monotherapy for epilepsy in children and young adults.
    Wilfong AA
    Pediatr Neurol; 2005 Feb; 32(2):77-80. PubMed ID: 15664764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zonisamide versus diazepam in the treatment of alcohol withdrawal syndrome.
    Rubio G; López-Muñoz F; Ponce G; Pascual JM; Martínez-Gras I; Ferre F; Jiménez-Arriero MÁ; Alamo C
    Pharmacopsychiatry; 2010 Nov; 43(7):257-62. PubMed ID: 20927698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy.
    Marinas A; Villanueva V; Giráldez BG; Molins A; Salas-Puig J; Serratosa JM
    Epileptic Disord; 2009 Mar; 11(1):61-6. PubMed ID: 19264587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zonisamide for absence seizures.
    Wilfong A; Schultz R
    Epilepsy Res; 2005; 64(1-2):31-4. PubMed ID: 15847848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zonisamide prophylaxis in refractory pediatric headache.
    Pakalnis A; Kring D
    Headache; 2006 May; 46(5):804-7. PubMed ID: 16643584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy.
    Shinnar S; Pellock JM; Conry JA
    Eur J Paediatr Neurol; 2009 Jan; 13(1):3-9. PubMed ID: 18343174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of zonisamide in patients with refractory partial-onset epilepsy.
    Wroe SJ; Yeates AB; Marshall A
    Acta Neurol Scand; 2008 Aug; 118(2):87-93. PubMed ID: 18547272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-inflicted lesions in dermatology: terminology and classification--a position paper from the European Society for Dermatology and Psychiatry (ESDaP).
    Gieler U; Consoli SG; Tomás-Aragones L; Linder DM; Jemec GB; Poot F; Szepietowski JC; de Korte J; Taube KM; Lvov A; Consoli SM
    Acta Derm Venereol; 2013 Jan; 93(1):4-12. PubMed ID: 23303467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flexible dosing of adjunctive zonisamide in the treatment of adult partial-onset seizures: a non-comparative, open-label study (ZEUS).
    Dupont S; Striano S; Trinka E; Springub J; Giallonardo AT; Smith P; Ellis S; Yeates A; Baker G
    Acta Neurol Scand; 2010 Mar; 121(3):141-8. PubMed ID: 20047564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of zonisamide in the treatment of alcohol dependence.
    Rubio G; López-Muñoz F; Ferre F; Martínez-Gras I; Ponce G; Pascual JM; Jiménez-Arriero MA; Alamo C
    Clin Neuropharmacol; 2010; 33(5):250-3. PubMed ID: 20811276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoxetine is an effective treatment for neurotic excoriations: case report.
    Gupta MA; Gupta AK
    Cutis; 1993 May; 51(5):386-7. PubMed ID: 8513691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zonisamide for migraine prophylaxis in refractory patients.
    Ashkenazi A; Benlifer A; Korenblit J; Silberstein SD
    Cephalalgia; 2006 Oct; 26(10):1199-202. PubMed ID: 16961786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life in patients with partial-onset seizures under adjunctive therapy with zonisamide: results from a prospective non-interventional surveillance study.
    Helmstaedter C; Stefan H; Witt JA
    Epileptic Disord; 2011 Sep; 13(3):263-76. PubMed ID: 21914589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low serum leptin level is associated with zonisamide-induced weight loss in overweight female epilepsy patients.
    Kim DW; Yoo MW; Park KS
    Epilepsy Behav; 2012 Apr; 23(4):497-9. PubMed ID: 22440324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.